AriBio joins UK study of AR1001 in cerebral small vessel disease

AriBio is partnering with Imperial College London and City St George’s, University of London on an MRC-funded study of AR1001 in cerebral small vessel disease. The trial could help clarify whether the drug affects brain blood flow and vascular function, informing future development in vascular cognitive impairment and dementia.

Why it matters: - Cerebral small vessel disease is a major cause of stroke and dementia. - The study could generate mechanistic evidence on whether AR1001 affects cerebral blood flow, cerebrovascular reactivity and blood-brain barrier function. - Results may help guide dose selection and later studies of AR1001 in vascular cognitive impairment and dementia.

What happened: - AriBio announced a collaboration with Imperial College London on MiroDose, an investigator-initiated experimental medicine study of AR1001, also known as mirodenafil. - The Imperial-sponsored study includes researchers from Imperial College London and City St George’s, University of London. - The project is supported by about £2.1 million from the United Kingdom’s Medical Research Council. - AriBio is the industry partner and will supply AR1001 and matched placebo. - AriBio will also conduct pharmacokinetic analyses of mirodenafil and key metabolites in participant samples.

The details: - MiroDose will study how phosphodiesterase type 5, or PDE5, inhibition affects cerebral blood flow and vascular function. - The randomized, double-blind, placebo-controlled crossover study plans to enroll 82 participants with MRI-confirmed cerebral small vessel disease. - Researchers will use advanced MRI, physiological assessments, blood biomarkers and cognitive testing. - The study will examine dose-related effects on cerebral blood flow, cerebrovascular reactivity and blood-brain barrier function. - Professor Alastair Webb of Imperial College London leads the study. - Professor Webb heads Imperial’s Small Vessel Disease Research Group and serves as Divisional Director of Research for Medicine and Integrated Care at Imperial College Healthcare NHS Trust. - Professor Atticus Hainsworth of City St George’s, University of London is part of the collaboration. - AriBio said its role brings drug-development expertise to the academic team’s cerebrovascular research. - The collaboration extends AriBio’s work on AR1001 into vascular mechanisms relevant to cognitive impairment. - AR1001 is a brain-penetrant PDE5 inhibitor that modulates nitric oxide–cyclic guanosine monophosphate, or NO–cGMP, signaling. - AR1001 is being developed for Alzheimer’s disease and other neurodegenerative disorders. - AriBio’s global Phase 3 POLARIS-AD trial in early Alzheimer’s disease enrolled 1,535 participants across 13 countries. - AR1001’s safety and efficacy for Alzheimer’s disease, cerebral small vessel disease and other dementia indications have not been established. - MiroDose is one of five experimental medicine studies backed by a broader £16.5 million MRC investment in dementia research.

Between the lines: - The partnership gives AriBio an academic setting to test a vascular hypothesis for AR1001 beyond Alzheimer’s disease. - The focus on endothelial dysfunction and PDE5 inhibition suggests the study is as much about biology as near-term treatment. - If the biomarker and imaging data are supportive, the program could strengthen AriBio’s case for pursuing vascular cognitive impairment as a follow-on indication. - Professor Webb said the collaboration is a step toward developing the first treatments for the commonest cause of vascular dementia.

What's next: - The study will enroll participants with MRI-confirmed cerebral small vessel disease. - Researchers will analyze exposure-response relationships using AriBio’s pharmacokinetic data alongside imaging and biomarker readouts. - Findings could inform future clinical trial design and dose selection for AR1001. - AriBio says the research may help guide development for patients with cerebral small vessel disease, where substantial unmet need remains. - For enrollment inquiries, contact the MiroDose study team.

The bottom line: - AriBio is using an MRC-backed UK academic study to test whether AR1001 may have value beyond Alzheimer’s disease, with cerebral small vessel disease as a new mechanistic and clinical target.